An update on thalassemia intermedia
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major
Optimal management of β thalassaemia intermedia
Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo
Optimal management of β thalassaemia intermedia
Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia
Age-related complications in treatment-naïve patients with thalassaemia intermedia
Thalassemia intermedia: Revisited
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia
Pregnancy outcome in patients with β-thalassemia intermedia at two tertiary care centers, in Beirut and Milan
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran
Stroke in thalassemia: A dilemma
Evaluation of the 5mg-g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia
Evaluation of the 5mg-g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia
Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients
Age-related complications in treatment-naïve patients with thalassaemia intermedia
Risk factors for pulmonary hypertension in patients with β thalassemia intermedia
A puzzling mutation in congenital erythropoietic porphyria and an association with β-thalassaemia trait